Abstract 1757P
Background
Breast cancer is a crucially prevailing cancer among women. Early detection and diagnosis of breast cancer are very important for patient survival. This study was conducted to devise a cost-effective and robust community-based breast cancer screening programme for LMIC.
Methods
All enrolled participants will undergo breast thermogram (BT) using an AI-based Thermalytix test along with clinical breast examination (CBE) by trained health workers. Women found suspicious in either CBE/BT or both will undergo confirmatory tests using Sonomammography (US) and/or Mammography; biopsy, where warranted, will be done to confirm the diagnosis. All symptomatic and asymptomatic women aged above 35 years of age, willing to give written informed consent for study participation were included. Those who are pregnant or lactating, treated for any cancers of breast/thorax, active inflammatory disorders on the skin of the breast, breast implants that can hamper testing using a BT or CBE were excluded from this study. The primary study endpoint is to evaluate the effectiveness of combined modality testing for breast cancer detection in healthy women. The benefit of a combined modality of Thermogram and clinical breast examination (CBE) for cancer detection rate were evaluated.
Results
A total of 3030 (both symptomatic and asymptomatic women) were screened for breast cancers over a period of 6months (Oct 2022 to April 2023). Women residing within a 120square kilometre radius were screened. Patients who were detected with screen abnormality on a thermogram B- Score 4 and above were 561 (18.51%). Six hundred and forty-six subjects (21.3%) who had an abnormality on both thermogram and CBE were recalled for further investigations. Out of which 5 subjects were detected with biopsy-proven breast malignancy (3 were early-stage breast cancer and 2 had locally advanced breast cancer).
Conclusions
Dual modality screening tool improves cancer detection rates, and this demonstrates the efficacy of these tools for breast cancer screening. Thermalytix with its artificial intelligence-based scoring system can assist the health care worker in the detection of breast cancer at a community level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Ravind.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23